PetMed Express, Inc. Stock

$3.13

3.30% yesterday

Nasdaq, Aug 12, 10:16 pm CET

ISIN

US7163821066

Symbol

PETS

Reports

Quarter | Annual

Index

NASDAQ Composite, Nasdaq Internet

Sector

Consumer Discretionary Distribution & Retail

Industry

Specialty Retail

Overview Dividends Analysts Charts News Strategies

PetMed Express, Inc. Stock price

$3.13

-29.00 90.26% 5Y

Nasdaq, Closing price Tue, Aug 12 2025

+0.10 3.30%

ISIN

US7163821066

Symbol

PETS

Reports

Quarter | Annual

Index

NASDAQ Composite, Nasdaq Internet

Sector

Consumer Discretionary Distribution & Retail

Industry

Specialty Retail

Key metrics

Basic

Market capitalization

$62.6m

Enterprise Value

$12.5m

Net debt

positive

Cash

$50.1m

Shares outstanding

20.7m

Valuation (TTM | estimate)

P/E

303.0 | negative

P/S

0.3 | 0.3

EV/Sales

0.1 | 0.1

EV/FCF

14.5

P/B

0.7

Dividends

DPS

$1.20

Yield 1Y | 5Y

39.6% | 4.2%

Growth 1Y | 5Y

0.0% | 7.1%

Payout 1Y | 3Y

12,000.0% | 137.0%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$247.0m | $233.3m

EBITDA

$8.4m | $3.5m

EBIT

$1.5m | $3.8m

Net Income

$360.0k | $-1.7m

Free Cash Flow

$860.0k

Growth (TTM | estimate)

Revenue

-10.8% | -17.0%

EBITDA

227.0% | 413.8%

EBIT

111.9% | 147.2%

Net Income

104.4% | 77.4%

Free Cash Flow

-50.0%

Financial Health

Equity Ratio

56.9%

Return on Equity

-7.7%

ROCE

1.6%

ROIC

0.3%

Debt/Equity

0.0

EPS

$0.0

FCF per Share

$0.0

Short interest

7.4%

Employees

287

Rev per Employee

$980.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

PetMed Express, Inc. Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a PetMed Express, Inc. forecast:

2x Hold

33%

4x Sell

67%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a PetMed Express, Inc. forecast:

Hold

33%

Sell

67%

Analyst Estimates with Stock Price Targets

Financial data from PetMed Express, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	247 247	11% 11% 100%
- Direct Costs	179 179	10% 10% 72%
Gross Profit	68 68	12% 12% 28%
- Selling and Administrative Expenses	60 60	29% 29% 24%
- Research and Development Expense	- -	- -
EBITDA	8.38 8.38	227% 227% 3%
- Depreciation and Amortization	6.86 6.86	12% 12% 3%
EBIT (Operating Income) EBIT	1.52 1.52	112% 112% 1%
Net Profit	0.36 0.36	104% 104% 0%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

PetMed Express, Inc. Stock News

Neutral

GlobeNewsWire

●

about 5 hours ago

PetMed Express, Inc. Announces Management Changes

DELRAY BEACH, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced that its Chief Executive Officer, Sandra Campos, and Chief Financial Officer, Robyn D'Elia, have resigned from their positions and employment with the Company.

Neutral

GlobeNewsWire

●

28 days ago

PETMED INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating PetMed Express, Inc. on Behalf of PetMed Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PetMed (PETS) To Contact Him Directly To Discuss Their Options

Neutral

GlobeNewsWire

●

about one month ago

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of PetMed Express, Inc. (NASDAQ: PETS) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

NEWTOWN, Pa., July 07, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving PetMed Express, Inc. (“PetMed”) (NASDAQ: PETS), resulting from allegations of providing potentially misleading business information to the investing public.

More PetMed Express, Inc. News

Company Profile

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Head office	United States
CEO	Sandra Campos
Employees	287
Founded	1996
Website	www.1800petmeds.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now